Authors of Hydroxychloroquine Study Retract Publication in Lancet Over Unverifiable Source Data
Sputnik – June 4, 2020
Since the promotion of hydroxychloroquine by US President Donald Trump as a possible treatment for those afflicted with the coronavirus, the drug has been the subject of controversy, as top medical journals rebuked the claim and major drug trials were halted.
Three authors of an article that claimed to have discovered that taking hydroxychloroquine led to an increased fatality risk among COVID-19 patients retracted the study on Thursday over concerns that the primary source data used to support the work was unverifiable.
According to the authors, Surgisphere, a data analytics company said to be responsible for providing the raw data, refused to supply the full dataset to an independent review. The authors then acknowledged that they “can no longer vouch for the veracity of the primary data sources”.
“We always aspire to perform our research in accordance with the highest ethical and professional guidelines. We can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards. Based on this development, we can no longer vouch for the veracity of the primary data sources” the authors said in a co-signed retraction letter.
The authors requested that the paper be retracted and apologised “for any embarrassment or inconvenience” they may have caused.
The research was published in the British medical journal The Lancet last month and garnered widespread response after appearing to imply that antimalarial drugs endorsed by US President Donald Trump as a COVID-19 treatment, were not just ineffective but potentially deadly to users.
Conclusions of the study suggested that coronavirus patients taking chloroquine or hydroxychloroquine showed irregular heartbeats and therefore faced a higher chance of dying while undergoing treatment.
Following the publishing of the study, the World Health Organisation (WHO) – which has been defunded by the White House amid the coronavirus pandemic – initially halted their trials of the malaria drug as a coronavirus treatment, but in the wake of the new findings have resumed trials on Wednesday.
The United Kingdom and France also shut down their clinical drug trials in the wake of the report.
Accusations of politically motivated condemnation have been leveled against those responsible for the data used in the study as an attempt to discredit the treatment touted by Trump. Demand for the drug has since skyrocketed.
Despite the retraction of the the study, however, a concurrent study published by the New England Journal of Medicine on Wednesday found there is no evidence that hydroxychloroquine helps prevent those taking the drug from becoming infected with the COVID-19 coronvirus.
Rush to trash hydroxychloroquine exposes fundamental flaws in profit-based medical ‘science’
By Helen Buyniski | RT | June 4, 2020
As the WHO and prestigious medical journal the Lancet back away from questionable data provided by healthcare analytics firm Surgisphere, ulterior motives for the rush to demonize hydroxychloroquine become clear.
The World Health Organization (WHO) sheepishly resumed testing the off-patent malaria drug hydroxychloroquine on coronavirus patients on Wednesday after pausing that arm of its ‘Solidarity’ clinical trial based on data that appeared to show the drug contributed to higher death rates among test subjects. That data, it turned out, came from a tiny US healthcare analytics firm called Surgisphere, and calling it faulty would be excessively charitable.
Not only is Surgisphere a company lacking in medical expertise – its employees included an “adult” entertainer and a science-fiction writer – but its CEO Sapan Desai co-authored two of the damning studies that used the firm’s data to smear hydroxychloroquine, already thoroughly demonized in the media thanks to its promotion by US President Donald Trump, as a killer. All data is sourced to a proprietary database supposedly containing a veritable ocean of real-time, detailed patient information yet curiously absent from existing medical literature.
The Surgisphere-tainted study appeared to show increased risk of in-hospital deaths and heart problems with no disease-fighting benefits, confirming the suspicions of medical-industry naysayers already inclined to hate the off-patent drug due to the lack of profit potential and Trump’s incessant boosterism. Italy, France, and Germany rushed to ban hydroxychloroquine, citing “an increased risk for adverse reactions with little or no benefit.”
But such a shameless character assassination performed against a potentially-lifesaving drug – especially one with a decades-long track record of safety in malaria, lupus, and arthritis patients that came highly recommended by some of the world’s most eminent disease experts, including France’s Didier Raoult – could only be accomplished with help from industry prejudice. It required ignoring numerous existing studies showing hydroxychloroquine was beneficial in treating early-stage Covid-19 patients, as well as anecdotal reports from thousands of doctors who’d successfully used it.
It also required trusting a fly-by-night company with next to no internet or media presence to make decisions that could affect the lives of millions of people. It’s not like there weren’t warning signs Surgisphere was something other than the top-notch medical analytics firm it presented itself as. The company began life as a textbook publisher in 2008 and hired most of its 11 employees two month ago, according to an investigation by the Guardian, yet it claimed ownership of a massive international database of 96,000 patients in 1,200 hospitals worldwide. One expert interviewed by the outlet said it would be difficult for even a national statistics agency to do in years what Surgisphere had supposedly done in weeks, calling the database “almost certainly a scam.” Yet no one at the Lancet or WHO thought to look a gift horse in the mouth – not when that gift drove a stake through the heart of hydroxychloroquine as Covid-19 treatment.
And while Australian researchers found flaws in the Surgisphere data just days after the May 22 publication of the Lancet study, noting that the number of Covid-19 deaths cited by the study as coming from five hospitals exceeded the entirety of Covid-19 deaths recorded in Australia at that time, the Lancet – instead of investigating just who this Surgisphere company really was, and why it had made such a glaring mistake – merely published a minor retraction related to the Australian data and put the controversy to bed.
The full-frontal assault on hydroxychloroquine was instead allowed to continue unchecked in the media, as mainstream outlets focused their energies on fluffing up remdesivir – a costly, untested drug manufactured by drug maker Gilead that has so far produced lackluster results in clinical trials – and stumping for an eventual vaccine. Hydroxychloroquine’s off-patent status meant it was a dead end as far as profits were concerned, while remdesivir and whatever vaccine is ultimately green-lighted will make a lot of people very rich. Perhaps hoping to throw their audiences off the real reason for their hydroxychloroquine hatred, several outlets hinted that Trump stood to make money off the drug (which costs about 60 cents per pill) – but even Snopes, no fan of the ‘Bad Orange Man’, had to pour cold water on that speculation.
The Lancet and New England Journal of Medicine have – belatedly – published “expressions of concern” about the Surgisphere hydroxychloroquine study, and an independent audit is being conducted. But the problem of biased health authorities selectively embracing some trial results while rejecting others is unlikely to stop there.
The Lancet study is hardly the only one to show hydroxychloroquine lacks efficacy in treating Covid-19. Multiple studies conducted by the US National Institutes of Health on hospitalized (i.e. severely-ill) coronavirus patients have yielded poor results, but even the drug’s most ardent evangelists acknowledge it doesn’t help end-stage or very sick patients. Raoult has even claimed France banned the drug’s use in all but the most severely ill patients in order to discredit it as a treatment. The US National Institutes of Health was publishing studies in its journal Virology touting chloroquine as “a potent inhibitor of SARS coronavirus infection” as far back as 2005, yet ‘coronavirus czar’ Anthony Fauci throws shade at the drug whenever he gets a chance.
As long as deadly diseases like Covid-19 are seen as profit sources first and human rights issues second (or third, or tenth…), treatments that aren’t profitable will always be marginalized in favor of costly and frequently less-effective pharmaceuticals. Drug industry profiteering has already killed hundreds of thousands – if not millions – of people in the US alone. Taking the profit motive out of healthcare can help ensure its body count stays as low as possible.
Helen Buyniski is an American journalist and political commentator at RT. Follow her on Twitter @velocirapture23
UK battery electric car strategy is ‘doomed to failure’
By Andrew Forster | Transport Xtra | June 1, 2020
The Government’s push to electrify road transport is based on naivety, the undue influence of the Committee on Climate Change, and a lack of engineering expertise within Government, an academic has said.
Professor Michael Kelly, the former chief scientific adviser to the Department for Communities and Local Government, issues the warning in a paper published by the Global Warming Policy Foundation.
He warns the Government’s ambitions for EVs and electric heating in buildings will end in damaging failure.
“When the penny drops and the progress towards all-electric UK is halted, we will be reminded of Ozymandias [two poems that describe how even the greatest men and the empires they forge are impermanent, their legacies fated to decay into oblivion – Ed].
“The rest of the world can look at Britain and choose whether to laugh or weep.”
On battery electric vehicles, he says: “Consider Dinorwig power station, the biggest hydropower energy storage plant in the UK. If all UK cars were battery powered, the nine gigawatts of energy stored behind the dam would be capable of recharging about 60,000 of them, or about 0.25 per cent of the UK fleet.”
If all vehicles have to be electric, “something of the order of 70 per cent of Britain’s entire existing electricity supply capacity will be needed”.
“When we get coded messages from the Climate Change Committee, implying that we will have to rethink the extent to which we are going to be able to travel in future, it is the implausibility of meeting that vast gulf in energy sources that is motivating them to question our lifestyles.”
Kelly points out that the Government’s net zero greenhouse gas target will also require the heating of buildings to be electrified using heat pumps. This will place huge additional demands on electricity supply, particularly in the winter.
Charging battery cars at night, when electricity demand from other sources is low, is only a “partial solution” to the problems, he says. “The current day-night variation in electricity demand is of itself too small to handle the extra load.
“Another suggestion is that we can charge cars during the day, when solar power is high. But in the absence of storage, this would mean charging them from mid-morning to mid-afternoon on sunny days. This is implausible too, and would be unreliable [even] if we could make it happen.”
Turning to local electricity supply issues, he says “we will be adding electric vehicle chargers and heat pumps to almost every home”.
“A fast EV charger for a car draws 7kW, perhaps for six hours, and a heat pump needs 3kW, potentially for much of the day. But the cabling and substations in most suburbs were sized and installed before these technologies were even thought of. So while there is sufficient headroom for electrification of a few households, the whole distribution system will need to be up- graded if demand grows.
“This work will be extraordinarily expensive, but without it there will either be regular ‘brownouts’, or drivers will have to be told where and when they can charge their batteries.”
Kelly dismisses battery storage as a major part of the solution. “The £45m battery installed by Elon Musk outside Adelaide, South Australia, can power that city for 30 minutes. If you wanted to be able to cover a week’s power outage after a major storm, it would cost around 1,300 times as much using batteries as it would with diesel generators. The idea is ludicrous.”
Turning to the raw materials needed to produce batteries, Kelly claims: “If we replace all of the UK vehicle fleet with EVs, and assuming they use the most resource-frugal next-generation batteries, we would need the following materials:
- 207,900 tonnes of cobalt – just under twice the annual global production;
- 264,600 tonnes of lithium carbonate – three-quarters of the world’s production;
- at least 7,200 tonnes of neodymium and dysprosium – nearly the entire world production of neodymium; and
- 2,362,500 tonnes of copper – more than half the world’s production in 2018.
“Put simply, we lack the ability to provide the infrastructure required to deliver electric cars and electric heating on the scale required by 2050.”
Kelly asks why we are trying to do so anyway and pins the blame on the Committee on Climate Change.
“An unelected body, the Committee displays many of the worst features of the administrative state. It has been grossly negligent in turning a blind eye to the complexity of electric vehicles and the related issue of the enforced switch to electricity for domestic heating.
“Committee members don’t have to face the consequences of their policies from voters; politicians, who do have to face the voters, hide behind the Committee in order to duck accountability.
“It is this failure of the UK’s political machinery that I believe is to blame for the situation in which we find ourselves.
“We have set out to decarbonise the economy without anyone having thought through all the engineering issues, let alone put a cost on the exercise.”
Kelly says that, with Covid-19, “it is clear that we will not be able to afford the costs of the net zero transition for decades, if ever”.
“To attempt to plough on would be madness; indeed, it would directly sabotage the UK economy, and without any measurable effect in terms of actually averting any climate change.”
“Surely now is the time for a root and branch cost-benefit review by independent engineers who have no skin in the game of electrifying the UK economy.”
Prince Charles sees ‘golden opportunity’ in Covid-19 pandemic as UK economy faces biggest recession in centuries
By Helen Buyniski | RT | June 4, 2020
The UK’s Prince Charles has said that the coronavirus crisis represents a global “reset moment” – one which seemingly allows leaders to ram through sustainability initiatives as cash-strapped citizens have no choice but to obey.
The virus’ “unprecedented shockwaves may well make people more receptive to big visions of change,” the heir to the British throne declared on Wednesday. He made the comments during a virtual meeting of the World Economic Forum’s Covid Action Platform, announcing the unveiling of his ‘Great Reset’ initiative. Charles cited the dramatic changes wrought by the pandemic as proof that a revolutionary shift was possible, glossing over the destruction the outbreak has wrought on the lives of average Brits to outline his ideal green future.
The project’s aim is to ensure businesses “build back better” in an environmentally-friendly fashion after shutdowns enacted in response to the epidemic left the UK economy in ruins. Businesses would be wise to “think big and act now,” the prince advised, noting “we have a unique, but rapidly shrinking, window of opportunity to learn lessons and reset ourselves on a more sustainable path.”
“It is an opportunity we have never had before and may never have again.”
While details of the royal’s big plan were somewhat elusive, buried under an avalanche of buzzwords, it involves a series of industry- and issue-specific roundtables, a social media networking component and “virtual hubs” aimed at attracting young people and “fostering innovation” through “thought leadership and practical solutions.” He called for a “paradigm shift” that “inspires action at revolutionary levels and pace,” taking inspiration from the rapid transformation of industries such as mobile technology and space exploration to interweave sustainability into the financial system.
It’s not like the UK is in a position to say no, he hinted, threatening naysayers with several flavors of climate-induced doom. “We have no alternative because otherwise, unless we take the action necessary, and we build again in a greener and more sustainable and more inclusive way, then we will end up having more and more pandemics and more and more disasters from ever-accelerating global warming and climate change,” the prince proclaimed.
While Prince Charles stressed in a promotional video accompanying the big reveal that “global warming, climate change, and the devastating loss of biodiversity” are the chief threats facing humanity, the majority of Britons are likely to be more concerned with the devastating recession threatening to engulf the nation completely. The Bank of England warned last month that the UK economy could shrink by 30 percent by the end of the summer. The central bank’s dire predictions – its first official forecast since the pandemic took hold – warned that GDP could decline by 14 percent for 2020, the sharpest single-year drop in over three centuries. And while the Bank of England claimed UK families entered the crisis “in a stronger position than they were before the 2008 financial crisis,” the Office of National Statistics revealed in April that the economy was already headed south even before the lockdown was imposed in March.
By the start of May, one-fifth of British retailers had permanently closed their doors, according to the British Chamber of Commerce. It also warned that while a third of the country’s economy was “shut down,” another third was only functioning “with some difficulty.” Some two-thirds of UK businesses have sought government assistance to pay furloughed staff, but help has been slow in coming. Still, the UK is behind only Singapore and Japan in terms of the amount of money it has pledged toward helping businesses recover from the crisis, earmarking the equivalent of 8.5 percent of its GDP – about £120 billion – for emergency loans, financing, and grants. This places the needy wholly at the mercy of the government – which, if Prince Charles has anything to say about it, will wrest serious sustainability concessions out of them before they’re allowed to go forward.
The UK has suffered greatly under the pandemic, recording the second-highest number of coronavirus deaths worldwide – over 39,000 as of Thursday, according to data collected by Johns Hopkins University. Public trust in the country’s response to the virus has also been shaken dramatically, with just 51 percent of respondents to a survey conducted last month reporting they approved of London’s handling of the epidemic – an 18-point drop over the previous month. Imperial College professor Neil Ferguson, the disgraced architect of the UK lockdown policy, probably didn’t help matters earlier this week when he quietly admitted his draconian stay-at-home restrictions were no better than Sweden’s no-lockdown response in terms of saving lives.
Helen Buyniski is an American journalist and political commentator at RT. Follow her on Twitter @velocirapture23
Staggering Death Rate in 7 US States
American deaths per million equal or exceed Europe’s worst-hit nations in several locales
click to enlarge
By Donna Laframboise | Big Picture News | June 3, 2020
At first glance, the United States appears to have fared reasonably well during this pandemic. So far, 327 Americans have died of the coronavirus out of every one million in the population.
That’s according to official numbers. Which are all we have to work with at the moment. (There are solid reasons why official numbers should be viewed as provisional and inexact. See the bottom of the page here.)
If we compare its overall rate of 327 deaths per million to the hardest hit nations in Europe, America looks blessed. Belgium has experienced 820 deaths per million. Spain and the UK, 580. Italy, 555.
But peer a bit closer, and another story emerges. America’s number is low because many parts of that country have (so far) been spared a serious outbreak. In places where the virus gained a foothold in the wider community, the death rate exceeds even the worst countries in Europe:
New York state: 1,546
New Jersey: 1,327
Connecticut: 1,114
Massachusetts: 1028
Rhode Island: 691
District of Columbia: 666
Louisiana: 611
Michigan: 556
This being an election year, some people are blaming US President Donald Trump, a Republican, for the lives lost. It’s worth observing, therefore, that the governor is a Democrat in six of the seven US states is which the death per million rate equals or surpasses Italy.
Likewise, the mayor of the District of Columbia is a Democrat. Only in Massachusetts is a Republican in charge.
Two U.S. senators determined to stop Nord Stream 2 by imposing extra sanctions
By Paul Antonopoulos | June 4, 2020
The Nord Stream 2 project involves the construction of two gas pipelines with a total capacity of 55 billion cubic meters of gas per year from Russia to Germany via the Baltic Sea. The gas pipeline will run through the territorial waters or exclusive economic zones of Russia, Finland, Sweden, Denmark and Germany. However, this gas pipeline is strengthening Russia’s relations with European states, making the U.S. desperate to end the project.
As reported by Bloomberg on Wednesday, U.S. senators are planning to extend sanctions against the Nord Stream 2 project. Sanctions are expected to target insurance companies associated with the project.
Senator Ted Cruz led the charge against Moscow and said the Russian pipeline is “a critical threat to America’s national security and must not be completed.” He added that Russian President Vladimir Putin is trying to circumvent the sanctions passed by Congress last year. He of course did not explain how a Russian pipeline a continent away from the U.S. and in northern Europe could impact their security.
Cruz, a Republican, was joined by Senator Jeanne Shaheen, a New Hampshire Democrat, who said that the pipeline “threatens Ukraine, Europe’s energy independence and gives Russia an opening to exploit our allies” and that “Congress must once again take decisive action and stand in this pipeline’s path.” He, just like Cruz, did not explain exactly how the pipeline is a threat or security concern, especially against Ukraine.
The pipeline does not threaten Europe’s energy independence, and rather, as is enshrined in a free market economy that the U.S. says it ardently defends, allows Europe to have another option for gas. Although Russian gas already reaches Europe, it goes via Ukraine that is volatile and a high risk for Russia. The Director General of the Ukrainian gas transportation system Sergei Makogon said earlier this year that Ukraine “will make every effort to prevent the completion of Nord Stream 2, as this project has a clear political character and runs counter to European principles of solidarity.”
With Russian gas to Europe at risk, the Nord Stream 2 project ensures Russia’s gas can reach European markets so it can compete with gas from Qatar, the U.S. and other sources. And here is where the problem lays for Washington. It is obviously absurd to suggest that Russian gas “threatens Ukraine” or is a “critical threat to America’s national security.” The proposed sanctions, that also have backing from Republican Senators John Barrasso of Wyoming and Ron Johnson of Wisconsin, are just part of the “gas wars” initiated by the U.S. to force countries to buy American liquefied natural gas.
Last week, former U.S. Ambassador to Germany, Richard Grenell, who resigned on June 2, said that new sanctions against Nord Stream 2 could be adopted by the U.S. Congress in an operational mode. Their purpose is to prevent commissioning of the gas pipeline.
At that time, media also swept on the news that an alleged dispute broke out between U.S. President Donald Trump and long-time German Chancellor Angela Merkel because of differences of opinion on the Nord Stream 2 project. However, neither Berlin nor Washington officially confirmed this rumour. Also, at the end of last year, the U.S. adopted a defense budget providing for sanctions on companies involved in laying the gas pipeline. As a result, the Swiss company Allseas stopped work and withdrew its ships. The head of the Ministry of Energy Alexander Nowak said after that Russia is able to complete the project itself however.
The Nord Stream 2 subsidiary, Gazprom Nord Stream 2, is building the gas pipeline. The annual meeting of Gazprom’s board of directors is scheduled for June 11 and it is expected the main topic of talks to be about the impact of Western sanctions on Gazprom and response measures. This is more crucial as now Poland has joined the U.S. in anti-Nord Stream 2 sanctions.
The Polish Office of Competition and Consumer Protection initiated a new proceeding against Gazprom regarding the construction of the Nord Stream 2 gas pipeline, threatening the Russian company with a fine of €50 million. The Polish office demanded that Gazprom provide documents regarding the project, namely contracts concluded between Gazprom’s subsidiary and other companies financing the construction of the gas pipeline. These were primarily contracts for the transmission, distribution, sale, supply and storage of gas fuels. Gazprom did not provide this information, and now Poland aims to fine the company.
Despite these pressures, in which Poland has a very minor part, Russia will unlikely be deterred by threats of sanctions. Russia has already learned long ago how to operate while under sanction and will continue to pursue projects that serve their state interests and integrate Russia closer to Europe. This is especially important as the European countries are more interested in convenient gas that is not only logistically easier, but cheaper than many other alternatives.
It is for this reason that Russian Ambassador to Washington, Anatoly Antonov, said that the U.S. will not be able to stop the construction of the Nord Stream 2 gas pipeline.
Paul Antonopoulos is an independent geopolitical analyst.
WHO says hydroxychloroquine trials for Covid-19 will RESUME as doubts emerge over side-effects research
RT | June 3, 2020
The World Health Organization has said that clinical trials involving the controversial drug hydroxychloroquine will resume, following doubts about US research which had led to their suspension.
WHO chief Tedros Adhanom Ghebreyesus said Wednesday that the trials of the anti-malarial drug for possible use against the novel coronavirus would be resumed, after they’d been paused over fears of increased death rates.
The world health body said there was no reason to modify its clinical trial of the drug, adding that experts had advised the continuation of “all arms” of the so-called Solidarity trial, including that concerning hydroxychloroquine.
Last week, Italy, France and Germany banned the use of the drug to treat Covid-19 patients, citing new clinical evidence indicating that there was “an increased risk for adverse reactions with little or no benefit.”
The much-publicized study in medical journal The Lancet could not confirm any benefit from the drug against Covid-19, and also reported that taking it was associated with increased risks of in-hospital deaths. However, serious questions have been raised about the data used in that study.
The research, by US-based company Surgisphere, began to unravel in recent weeks as experts noticed red flags and questioned the credulity of its data-gathering and reporting. The Lancet journal issued an “expression of concern” over the study on Wednesday.
A Guardian investigation found that Surgisphere’s employees “have little or no data or scientific background,” with one appearing to be a sci-fi author and fantasy artist. The firm’s chief executive Sapan Desai has been named in three medical malpractice suits, the outlet said.
One WHO expert said hopefully trials of the drug will continue until there is a “definitive” answer on whether or not it works, Reuters reported.